David Lee received his B.S. in biology from Stanford University and his PhD in biochemistry from the University of Washington. With the support of the Helen Hay Whitney Foundation, he completed postdoctoral fellowships at Washington University (biochemistry) and the University of Washington (pharmacology). From 1983 to 1985, he was a senior scientist at Oncogen, which was acquired by Bristol Myers Squibb during this period. In 1985, Lee joined the University of North Carolina at Chapel Hill as a member of the Lineberger Comprehensive Cancer Center and a faculty member in the Department of Microbiology and Immunology. In 1991 he was appointed Scientific Program Leader for Cell Biology in the Lineberger Comprehensive Cancer Center, and in 1998 he was appointed the head of the Department of Biochemistry and Biophysics. In 2005, Lee moved to the University of Georgia to become the vice president for research and executive vice president of the UGA Research Foundation, with an appointment as professor of biochemistry and molecular biology. He has served on the boards of several national organizations, including the Southeastern University Research Association, the U.S. Department of Energy’s Center for BioEnergy Innovation, and Oak Ridge Associated Universities (ORAU). He was elected a Fellow of the American Association for the Advancement of Science in 2004. His research has focused on the transformation from normal to cancer cells.